Scarica l'app Stockscreener
98.15
2.87%
2.74
Dopo l'orario di chiusura:
98.76
0.61
+0.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$95.41
Aprire:
$95.005
Volume 24 ore:
2.89M
Relative Volume:
1.33
Capitalizzazione di mercato:
$13.93B
Reddito:
$4.34B
Utile/perdita netta:
$-965.00M
Rapporto P/E:
-16.17
EPS:
-6.07
Flusso di cassa netto:
$869.00M
1 W Prestazione:
+7.24%
1M Prestazione:
+19.35%
6M Prestazione:
-26.55%
1 anno Prestazione:
-6.97%
Intervallo 1D:
$95.00
$100.15
Intervallo di 1 settimana:
$90.30
$100.15
Portata 52W:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
98.15 | 13.93B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
421.47 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
201.10 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
542.65 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.45 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
162.61 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Infinity Bio Secures $8M Series A and Acquires Serimmune to Dominate Antibody Reactome Market - Stock Titan
DNA/Gene Microarray Market Future Trends and Scope Analysis - openPR.com
How the DNA Data Storage Market Will Evolve by 2032Growth, - openPR.com
Saudia Arabia Introduces Strategic Healthcare Vision and Global Partnerships at BIO 2025 - GlobeNewswire Inc.
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Illumina and Science Centre Singapore partner for Brain Fest 2025 - Illumina
Video: Inspiring the next generation of scientists in Singapore - Illumina
Clinical Oncology Next Generation Sequencing Market Detailed - openPR.com
Illumina (ILMN) Price Target Boosted by Canaccord Analyst | ILMN Stock News - GuruFocus
Video: Two Illumina scientists share their “why” - Illumina
Breaking Down Illumina: 11 Analysts Share Their Views - Benzinga
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - Illumina
Lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics - marketscreener.com
Piper Sandler maintains Illumina stock Overweight, $185 target By Investing.com - Investing.com UK
Long Read Sequencing Market Top Key Players Analysis - openPR.com
Gemeinsam Genomik neu denken - Illumina
Microarray Biochips Market is Booming Worldwide |Illumina,Qiagen,Eppendorf - openPR.com
Single-cell Omics Market Projected to Witness Growth with - openPR.com
Tumor-Derived Exosomes Market Set to Witness Significant - openPR.com
Hereditary Testing Market Future Business Opportunities - openPR.com
Next Generation Sequencing Market to Witness Upsurge in Growth - openPR.com
Does Illumina (ILMN) Have Good Long-Term Growth Prospects? - Insider Monkey
Nucleic Acid Isolation and Purification Market Size, Trends & - openPR.com
Illumina’s DNA Test Tech Infringes Hospital Patent, Suit Claims - Bloomberg Law News
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com
Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo Finance
Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com
Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com
Illumina Connected Insights - Technology Networks
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Nasdaq
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com South Africa
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Insider Monkey
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - Nasdaq
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo Finance
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Illumina Inc Azioni (ILMN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Thaysen Jacob | Chief Executive Officer |
May 12 '25 |
Buy |
80.88 |
6,500 |
525,732 |
77,540 |
| Thaysen Jacob | Chief Executive Officer |
May 13 '25 |
Buy |
80.84 |
5,850 |
472,942 |
83,390 |
0.17%
2.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):